Fig. 7
AAA-CD4+ T-cell therapy induces systemic and persistent antitumor immunity. AAA-CD4+ T cells were produced from BALB/c mouse CD4+ T cells in cultures activated with B6-derived GM-DCs. a-b: Host B6 mice were inoculated with the same amount of B16F1 cells (1 × 106) on the left and right flanks of the mice on day zero. AAA-CD4+ T cells were intratumorally injected into the left side of the tumor. PBS-injected mice were used as controls. Tumor growth on both sides of each mouse (a) and survival (b) are shown. The data are pooled from two independent experiments. c-d: Nine days after inoculation with 0.5 × 106 B16F1 cells, AAA-CD4+ T cells were intratumorally injected into the host B6 mice. The mice that survived AAA-CD4+ T-cell therapy were maintained for 6 months. Subsequently, the surviving mice were subcutaneously injected with 2.5 × 106 B16F1 cells as a re-challenge for the same tumor. Naïve B6 mice were used as controls. Tumor growth (c) and survival (d) are shown. ***P < 0.001. The data are pooled from two independent experiments